A 10-year-old child with idiopathic growth hormone deficiency was treated with recombinant methionyl human growth hormone (m-hGH, Somatonorma(R))
(5.6cm/y).
The cause of growth attenuation during m-hGH treatment was again from 126.6 to 132.2cm during the next 12 months of p-hGH treatment concluded to be the high titer of anti-hGH antibody. This is the first case in Japan and one of only three cases in which growth attenuation occurred during m-hGH treatment.
Treatment of growth-hormone-deficient children with recombinant methionyl human growth hormone (m-hGH) has been studied since 1982. By several investigators it has been confirmed that the growth promoting effect of m-hGH is comparable to that of pituitary-extracted hGH (p-hGH) (Takano et al., 1983 , Bierich 1986 , Takano and Shizume 1986 , Takano et al.. 1986 , Milner et al., 1986 , Girard and Gourmelen 1986 , Vincens-Colvet 1986 , Westphal 1986 , Kaplan et al., 1986 , Bierich et al., 1986 . The only apparent difference between the result of m-hGH treatment and that of p-hGH treatment was the great antigenicity of m-hGH. In a Japanese study (Takano et al., 1986) , 
